Literature DB >> 24821922

Immune responses during spontaneous control of HIV and AIDS: what is the hope for a cure?

A Saez-Cirion1, B Jacquelin, F Barré-Sinoussi, M Müller-Trutwin.   

Abstract

HIV research has made rapid progress and led to remarkable achievements in recent decades, the most important of which are combination antiretroviral therapies (cART). However, in the absence of a vaccine, the pandemic continues, and additional strategies are needed. The 'towards an HIV cure' initiative aims to eradicate HIV or at least bring about a lasting remission of infection during which the host can control viral replication in the absence of cART. Cases of spontaneous and treatment-induced control of infection offer substantial hope. Here, we describe the scientific knowledge that is lacking, and the priorities that have been established for research into a cure. We discuss in detail the immunological lessons that can be learned by studying natural human and animal models of protection and spontaneous control of viraemia or of disease progression. In particular, we describe the insights we have gained into the immune mechanisms of virus control, the impact of early virus-host interactions and why chronic inflammation, a hallmark of HIV infection, is an obstacle to a cure. Finally, we enumerate current interventions aimed towards improving the host immune response.

Entities:  

Keywords:  HIV controllers; eradication; inflammation; natural hosts of simian–human immunodeficiency virus; post-treatment controllers

Mesh:

Year:  2014        PMID: 24821922      PMCID: PMC4024229          DOI: 10.1098/rstb.2013.0436

Source DB:  PubMed          Journal:  Philos Trans R Soc Lond B Biol Sci        ISSN: 0962-8436            Impact factor:   6.237


  247 in total

1.  Natural killer cells in HIV controller patients express an activated effector phenotype and do not up-regulate NKp44 on IL-2 stimulation.

Authors:  Francesco Marras; Elena Nicco; Federica Bozzano; Antonio Di Biagio; Chiara Dentone; Emanuele Pontali; Silvia Boni; Maurizio Setti; Giancarlo Orofino; Eugenio Mantia; Valentina Bartolacci; Francesca Bisio; Agostino Riva; Roberto Biassoni; Lorenzo Moretta; Andrea De Maria
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-01       Impact factor: 11.205

Review 2.  HIV controllers: a genetically determined or inducible phenotype?

Authors:  Asier Sáez-Cirión; Gianfranco Pancino
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

3.  Response: Maraviroc intensification and microbial translocation.

Authors:  Peter W Hunt; Michael M Lederman; Steven G Deeks
Journal:  Blood       Date:  2013-09-26       Impact factor: 22.113

4.  Maraviroc-induced decrease in circulating bacterial products is not linked to an increase in immune activation in HIV-infected individuals.

Authors:  Christina Psomas; Jean-Philippe Lavigne; Claudine Barbuat; Selma Trabelsi; Jade Ghosn; Caroline Lascoux-Combe; Philippe Flandre; Lise Cuzin; Jacques Reynes; Brigitte Autran; Pierre Corbeau
Journal:  Blood       Date:  2013-09-26       Impact factor: 22.113

Review 5.  HIV-associated chronic immune activation.

Authors:  Mirko Paiardini; Michaela Müller-Trutwin
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

6.  Intact type I Interferon production and IRF7 function in sooty mangabeys.

Authors:  Steven E Bosinger; Zachary P Johnson; Kathryn A Folkner; Nirav Patel; Tayebeh Hashempour; Simon P Jochems; Perla M Del Rio Estrada; Mirko Paiardini; Rongtuan Lin; Thomas H Vanderford; John Hiscott; Guido Silvestri
Journal:  PLoS Pathog       Date:  2013-08-29       Impact factor: 6.823

7.  TRIM5 alpha drives SIVsmm evolution in rhesus macaques.

Authors:  Fan Wu; Andrea Kirmaier; Robert Goeken; Ilnour Ourmanov; Laura Hall; Jennifer S Morgan; Kenta Matsuda; Alicia Buckler-White; Keiko Tomioka; Ronald Plishka; Sonya Whitted; Welkin Johnson; Vanessa M Hirsch
Journal:  PLoS Pathog       Date:  2013-08-22       Impact factor: 6.823

8.  Major histocompatibility complex class I haplotype diversity in Chinese rhesus macaques.

Authors:  Julie A Karl; Patrick S Bohn; Roger W Wiseman; Francesca A Nimityongskul; Simon M Lank; Gabriel J Starrett; David H O'Connor
Journal:  G3 (Bethesda)       Date:  2013-07-08       Impact factor: 3.154

9.  Kinetics of myeloid dendritic cell trafficking and activation: impact on progressive, nonprogressive and controlled SIV infections.

Authors:  Viskam Wijewardana; Jan Kristoff; Cuiling Xu; Dongzhu Ma; George Haret-Richter; Jennifer L Stock; Benjamin B Policicchio; Adam D Mobley; Rebecca Nusbaum; Hadega Aamer; Anita Trichel; Ruy M Ribeiro; Cristian Apetrei; Ivona Pandrea
Journal:  PLoS Pathog       Date:  2013-10-03       Impact factor: 6.823

10.  APOBEC3G polymorphism as a selective barrier to cross-species transmission and emergence of pathogenic SIV and AIDS in a primate host.

Authors:  Annabel Krupp; Kevin R McCarthy; Marcel Ooms; Michael Letko; Jennifer S Morgan; Viviana Simon; Welkin E Johnson
Journal:  PLoS Pathog       Date:  2013-10-03       Impact factor: 6.823

View more
  11 in total

1.  Natural killer cells migrate into and control simian immunodeficiency virus replication in lymph node follicles in African green monkeys.

Authors:  Nicolas Huot; Beatrice Jacquelin; Thalia Garcia-Tellez; Philippe Rascle; Mickaël J Ploquin; Yoann Madec; R Keith Reeves; Nathalie Derreudre-Bosquet; Michaela Müller-Trutwin
Journal:  Nat Med       Date:  2017-10-16       Impact factor: 53.440

Review 2.  Mathematical Models of HIV Latency.

Authors:  Alison L Hill
Journal:  Curr Top Microbiol Immunol       Date:  2018       Impact factor: 4.291

3.  Cellular Immune Response Induced by DNA Immunization of Mice with Drug Resistant Integrases of HIV-1 Clade A Offers Partial Protection against Growth and Metastatic Activity of Integrase-Expressing Adenocarcinoma Cells.

Authors:  Maria Isaguliants; Olga Krotova; Stefan Petkov; Juris Jansons; Ekaterina Bayurova; Dzeina Mezale; Ilze Fridrihsone; Athina Kilpelainen; Philip Podschwadt; Yulia Agapkina; Olga Smirnova; Linda Kostic; Mina Saleem; Oleg Latyshev; Olesja Eliseeva; Anastasia Malkova; Tatiana Gorodnicheva; Britta Wahren; Ilya Gordeychuk; Elizaveta Starodubova; Anastasia Latanova
Journal:  Microorganisms       Date:  2021-06-04

4.  Preface. The science of infectious diseases.

Authors:  Christopher Dye; Anne O'Garra
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2014-05-12       Impact factor: 6.237

Review 5.  Chloroquine and beyond: exploring anti-rheumatic drugs to reduce immune hyperactivation in HIV/AIDS.

Authors:  Andrea Savarino; Iart Luca Shytaj
Journal:  Retrovirology       Date:  2015-06-18       Impact factor: 4.602

6.  Second European Round Table on the Future Management of HIV: 10-11 October 2014, Barcelona, Spain.

Authors:  Casper Rokx; Douglas D Richman; Michaela Müller-Trutwin; Guido Silvestri; Jan Lunzen; Saye Khoo; Mathias Lichterfeld; Marcus Altfeld; Carlo Federico Perno; Peter W Hunt; Paddy Mallon; Jürgen K Rockstroh; Anton L Pozniak; Bonaventura Clotet; Charles Ab Boucher
Journal:  J Virus Erad       Date:  2015-07-01

7.  Codon optimization and improved delivery/immunization regimen enhance the immune response against wild-type and drug-resistant HIV-1 reverse transcriptase, preserving its Th2-polarity.

Authors:  A A Latanova; S Petkov; A Kilpelainen; J Jansons; O E Latyshev; Y V Kuzmenko; J Hinkula; M A Abakumov; V T Valuev-Elliston; M Gomelsky; V L Karpov; F Chiodi; B Wahren; D Y Logunov; E S Starodubova; M G Isaguliants
Journal:  Sci Rep       Date:  2018-05-24       Impact factor: 4.379

8.  Systemic DPP4 activity is reduced during primary HIV-1 infection and is associated with intestinal RORC+ CD4+ cell levels: a surrogate marker candidate of HIV-induced intestinal damage.

Authors:  Mickaël J Ploquin; Armanda Casrouge; Yoann Madec; Nicolas Noël; Beatrice Jacquelin; Nicolas Huot; Darragh Duffy; Simon P Jochems; Luca Micci; Camille Lécuroux; Faroudy Boufassa; Thijs Booiman; Thalia Garcia-Tellez; Mathilde Ghislain; Roger Le Grand; Olivier Lambotte; Neeltje Kootstra; Laurence Meyer; Cecile Goujard; Mirko Paiardini; Matthew L Albert; Michaela Müller-Trutwin
Journal:  J Int AIDS Soc       Date:  2018-07       Impact factor: 5.396

Review 9.  Antibody-Mediated Therapy against HIV/AIDS: Where Are We Standing Now?

Authors:  Noel Jacques Awi; Sin-Yeang Teow
Journal:  J Pathog       Date:  2018-06-03

Review 10.  Atherosclerosis in HIV Patients: What Do We Know so Far?

Authors:  Anastasia V Poznyak; Evgeny E Bezsonov; Evgeny E Borisov; Andrey V Grechko; Andrey G Kartuesov; Alexander N Orekhov
Journal:  Int J Mol Sci       Date:  2022-02-24       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.